The Drugs and Magic Remedies Act: Which Health Claims Are Banned Outright

This article is for clinic owners, practice managers and marketing leads in India who have heard that "the Magic Remedies Act" bans some health claims and want to know which ones, in plain terms. It reads the Act itself, section by section, and then shows how it sits next to the National Medical Commission's October 2026 advertising notice.

The short answer is that the Act is narrower than most people assume and sharper than most people expect. It regulates advertisements that refer to a drug or a magic remedy. It does not ban every cure claim by every provider. But where it applies, the wording test is about what the advertisement suggests to the reader, and the schedule of named conditions is fixed in the statute. We are a marketing team, not a law firm. Treat this as a briefing for your counsel, not as legal advice.

What the Act regulates

The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 defines an advertisement very widely. It covers notices, circulars, labels and wrappers, and oral announcements, as well as light, sound or smoke-based ones. A WhatsApp forward, a reel voice-over and a banner at a health camp all fall within that definition in ordinary reading.

"Drug" covers medicines for internal or external use, substances used to diagnose or treat disease, articles other than food that affect the structure or functioning of the body, and components of those articles. "Magic remedy" covers talismans, mantras and charms said to have miraculous healing effects.

Three sections carry the weight:

• Section 3 bars advertisements that refer to a drug in terms that suggest, or are calculated to lead to, its use for certain listed purposes.
• Section 4 bars drug advertisements that give a false impression of the drug's nature, make false claims, or are otherwise materially false or misleading.
• Section 5 bars anyone who practises magic remedies from advertising them as effective for the purposes in section 3.

Notice the phrase "calculated to lead to". The question is not whether you used the word "cure". It is whether the advertisement, read by an ordinary patient, points them towards using that drug for a prohibited purpose.

The four outright bans in section 3

Section 3 lists purposes for which a drug may not be advertised. The text of the Act, as reproduced on BnB Legal's bare-act page, groups them like this:

The schedule can be extended by rules, but only for conditions that need timely medical treatment or have no accepted remedy, and only after consulting the Drugs Technical Advisory Board. So the list you work from is the statutory list plus anything added by rule. Ask your counsel to confirm whether any additions are in force when you build your checklist.

The Schedule, grouped for marketers

The Schedule has 54 entries. Several use older terminology ("dropsy", "insanity", "fits"), so map each to its modern clinical meaning with your clinical lead and counsel rather than guessing from the label. The entries that most often meet clinic marketing:

Three of those are worth a second look. "Obesity", "stature of persons" and "forms and structure of the female bust" catch weight-loss, height-growth and aesthetic-enhancement products, which many clinics sell alongside their procedures. "Sterility in women" and "sexual impotence" sit next to fertility and men's health programmes. "Diabetes", "cancer" and "heart diseases" sit next to the most common cure-claim pattern in Ayurvedic and wellness advertising.

Section 4 applies even when the condition is not scheduled

Many teams stop reading at the Schedule. Section 4 is separate. A drug advertisement for a common cold remedy, a joint supplement or a skin cream can be unlawful if it creates a false impression of what the drug is, claims something that is false, or misleads in a material way. Substantiation therefore matters even for conditions that are nowhere near the Schedule.

Who is liable, and for what

Section 7 sets the penalties. A first conviction can bring imprisonment up to six months, a fine, or both. A later conviction can bring up to one year, a fine, or both. Section 8 lets an authorised gazetted officer enter premises where an offence is suspected, seize the advertisements and examine records.

Section 9 is the one marketing teams should read twice. Where a company commits the offence, the company and the people in charge of its business at the time are liable. A person can escape if they prove the offence happened without their knowledge or that they exercised all due diligence. Directors, managers and other officers are also liable if the offence involved their consent or connivance, or came from their neglect. "Company" includes a firm or association. A hospital group, a partnership clinic and a wellness brand are all within that reading.

The Act also treats printing and publishing as taking part in the publication. That is the reason an agency's "we only posted it" does not help the client, and why the NMC notice makes a similar point in paragraph 4.4.

The exceptions are narrow

Section 14 lists what the Act does not cover. Four items matter here:

• A registered medical practitioner's signboard at their premises indicating treatment for scheduled conditions
• Genuine scientific or social treatises and books on those subjects
• Drug advertisements sent confidentially only to registered medical practitioners, in the prescribed manner
• Advertisements published by the Government

The signboard exception does not stretch to Instagram, Google Business Profile or a landing page. It is about the physical board at the practice. Whether a doctor's signboard may say anything at all is also governed by the NMC rules, which we cover in our complete guide to NMC advertising rules.

Enforcement is no longer theoretical

For decades the Act was rarely used against ordinary clinic marketing. That has changed in the last two years. On 26 March 2025 the Supreme Court directed states to implement the Act, including appointing enforcement officers and setting up grievance mechanisms, and on 11 August 2025 it disposed of the long-running petition while recording that earlier order, as reported by LiveLaw.

The advertising self-regulator ASCI is also routing cases to the state. Its 2024-25 annual complaints report, summarised by South First, says it referred 233 health advertisements to the Ministry of Ayush for suspected breaches of this Act, many of them promising cures for cancer, diabetes or sexual weakness. A complaint can therefore start with a competitor, a patient or a self-regulator and end up with a state officer.

How this fits with the NMC notice

On 6 October 2026 the NMC issued its Guidelines on Ethical Advertising and Public Communication. Paragraph 8.1(iii) bars doctors from advertising "Guaranteed cures", "100% success" and "Miracle treatment", and paragraph 8.1(vi) bars statements that create unrealistic expectations, conceal risks or promote unproven or secret remedies. Our summary of what changed is in this article on the 2026 NMC guidelines.

The two regimes overlap but are not the same. The NMC notice binds registered medical practitioners and, through the Clinical Establishments framework, hospitals. The 1954 Act binds anyone who takes part in publishing a covered advertisement, including a wellness brand with no doctor in the picture. A claim can pass one test and fail the other, so check against both.

A working test for your copy

Run each draft through five questions before it leaves the content calendar:

1. Does the copy refer to a drug, a named formulation, a supplement positioned as treatment, or a device that acts on the body?
2. Does it name or clearly point to a scheduled condition, or to sexual capacity, contraception or menstrual correction?
3. Would an ordinary reader take it as advice to use that product for that purpose?
4. Does any claim go beyond what the product's licence and evidence support?
5. Is anyone outside the clinical team approving the claim, and is the approval dated and filed?

Hypothetical rewrites, to show the direction rather than to give approved wording:

Every row of the safer column still needs clinical review and, where a product is involved, legal review. Keep a claim register with the wording, the evidence, the approver and the date. If a complaint arrives, that register is your due-diligence record under section 9.

Where to start

Audit the last twelve months of copy for every product you name. Pull out any page, post or message that pairs a product with a scheduled condition. Take those down first, then rebuild the educational content in the doctor's own name. Our compliance hub lists the other regimes that touch Indian healthcare advertising, and the glossary entry on medical advertising regulations gives the short definitions your team can share.